🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07840196
Recruiting Phase 1

NG004 in Incomplete Spinal Cord Injury Patients

NCT07840196 · tracked via the Priya Life Science Germany tracker
Sponsor
NovaGo Therapeutics AG
Phase
Phase 1
Started
2026-08-05
Last updated
2026-09-24

Condition(s) studied

Acute Spinal Cord Injury (SCI)Spinal Cord DiseasesSpinal Cord InjuriesTrauma Nervous System

Investigational drug(s) / intervention(s)

NG004 →Placebo

NG004: repeated intrathecal injections of NG004 within 30 days

Placebo: repeated intrathecal injections of Placebo within 30 days

Study summary

This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening * 4-28 days post-injury and no earlier than 4 days after spinal surgery * No required mechanical ventilation or patients that do not completely depend on mechanical ventilation * Hemodynamically and clinical stable patient according to the acute SCI condition at baseline Exclusion Criteria: * Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds * Multiple levels of clinically relevant spinal cord lesions * Major brachial or lumbar plexus damage/trauma * Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function * Other significant pre-existing or current severe systemic disease * History of or an episode of multiple sclerosis or Guillain-Barre syndrome * History of recent meningitis or meningoencephalitis * History of refractory epilepsy * Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI * Presence of any unstable medical or psychiatric condition * Drug dependence any time within the last 6 months before Screening * Pregnant or nursing women * History of a life-threatening allergic or immune-mediated reaction * Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations * Patients who are unconscious

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Klinik für Querschnittgelähmte, Klinikum Bayreuth Bayreuth Germany Recruiting
BG Universitätsklinikum Bergmannsheil Bochum Germany Not Yet Recruiting
Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost Halle Germany Not Yet Recruiting
BG Klinikum Hamburg Hamburg Germany Not Yet Recruiting
Klinik für Paraplegiologie, Universitätsklinikum Heidelberg Heidelberg Germany Not Yet Recruiting
Zentrum für Rückenmarksverletzte, Unfallklinik Murnau Murnau am Staffelsee Germany Not Yet Recruiting
BG Klinik Tübingen Tübingen Germany Recruiting
REHAB Basel Basel Switzerland Recruiting
Swiss Paraplegic Centre Nottwil Switzerland Recruiting
Universitätsklinik Balgrist Zurich Switzerland Recruiting

More NovaGo Therapeutics AG trials in Germany

NG004 in Spinal Cord Injury Patients Active, not recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07840196 on ClinicalTrials.gov ↗ ← All trials in Germany